Randomized Trial: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer – NEJM Journal Watch (free) AND Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC – Cancer Therapy Advisor (free)